Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Defective p53 signaling in p53 wild-type tumors attenuates p21^waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G₂ arrest

  Aime A. Levesque, Andrew A. Fanous, Alissa Poh and Alan Eastman

  Mol Cancer Ther February 1 2008 7 (2) 252-262; DOI:10.1158/1535-7163.MCT-07-2066

  
  
• Research Articles: Therapeutics, Targets, and Development

  A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction

  Hailan Liu, Yang Liu and Jian-Ting Zhang

  Mol Cancer Ther February 1 2008 7 (2) 263-270; DOI:10.1158/1535-7163.MCT-07-0445

  
  
• Research Articles: Therapeutics, Targets, and Development

  The role of TRPV6 in breast carcinogenesis

  Katrin A. Bolanz, Matthias A. Hediger and Christopher P. Landowski

  Mol Cancer Ther February 1 2008 7 (2) 271-279; DOI:10.1158/1535-7163.MCT-07-0478

  
  
• Research Articles: Therapeutics, Targets, and Development

  Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers

  Jianbo Wang, Ryan Day, Yiyu Dong, Steven J. Weintraub and Loren Michel

  Mol Cancer Ther February 1 2008 7 (2) 280-285; DOI:10.1158/1535-7163.MCT-07-2003

  
  
• Research Articles: Therapeutics, Targets, and Development

  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

  Min Li, Uddalak Bharadwaj, Rongxin Zhang, Sheng Zhang, Hong Mu, William E. Fisher, F. Charles Brunicardi, Changyi Chen and Qizhi Yao

  Mol Cancer Ther February 1 2008 7 (2) 286-296; DOI:10.1158/1535-7163.MCT-07-0483

  
  
• Research Articles: Therapeutics, Targets, and Development

  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells

  Adly Yacoub, Margaret A. Park, Pankaj Gupta, Mohammed Rahmani, Guo Zhang, Hossein Hamed, David Hanna, Devanand Sarkar, Irina V. Lebedeva, Luni Emdad, Moira Sauane, Nicollaq Vozhilla, Sarah Spiegel, Costas Koumenis, Martin Graf, David T. Curiel, Steven Grant, Paul B. Fisher and Paul Dent

  Mol Cancer Ther February 1 2008 7 (2) 297-313; DOI:10.1158/1535-7163.MCT-07-2166

  
  
• Research Articles: Therapeutics, Targets, and Development

  Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling

  Adly Yacoub, Pankaj Gupta, Margaret A. Park, Mohammed Rhamani, Hossein Hamed, David Hanna, Guo Zhang, Devanand Sarkar, Irina V. Lebedeva, Luni Emdad, Costas Koumenis, David T. Curiel, Steven Grant, Paul B. Fisher and Paul Dent

  Mol Cancer Ther February 1 2008 7 (2) 314-329; DOI:10.1158/1535-7163.MCT-07-2150

  
  
• Research Articles: Therapeutics, Targets, and Development

  A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells

  Andreas Vogt, Peter R. McDonald, Aletheia Tamewitz, Rachel P. Sikorski, Peter Wipf, John J. Skoko III and John S. Lazo

  Mol Cancer Ther February 1 2008 7 (2) 330-340; DOI:10.1158/1535-7163.MCT-07-2165

  
  
• Research Articles: Therapeutics, Targets, and Development

  Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27^kip

  Zhiwei Wang, Bennett W. Yu, KM Wahidur Rahman, Fakhara Ahmad and Fazlul H. Sarkar

  Mol Cancer Ther February 1 2008 7 (2) 341-349; DOI:10.1158/1535-7163.MCT-07-0476

  
  
• Research Articles: Therapeutics, Targets, and Development

  CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo

  Shih-Wei Wang, Shiow-Lin Pan, Yu-Chun Huang, Jih-Hwa Guh, Po-Cheng Chiang, Der-Yi Huang, Sheng-Chu Kuo, Kuo-Hsiung Lee and Che-Ming Teng

  Mol Cancer Ther February 1 2008 7 (2) 350-360; DOI:10.1158/1535-7163.MCT-07-2000

  
  
• Research Articles: Therapeutics, Targets, and Development

  Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

  Andrea Cavazzoni, Roberta R. Alfieri, Caterina Carmi, Valentina Zuliani, Maricla Galetti, Claudia Fumarola, Raffaele Frazzi, Mara Bonelli, Fabrizio Bordi, Alessio Lodola, Marco Mor and Pier Giorgio Petronini

  Mol Cancer Ther February 1 2008 7 (2) 361-370; DOI:10.1158/1535-7163.MCT-07-0477

  
  
• Research Articles: Therapeutics, Targets, and Development

  6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1–mediated MDR in small cell lung cancer

  Giuseppe Filomeni, Paola Turella, Maria Luisa Dupuis, Olindo Forini, Maria Rosa Ciriolo, Maurizio Cianfriglia, Silvia Pezzola, Giorgio Federici and Anna Maria Caccuri

  Mol Cancer Ther February 1 2008 7 (2) 371-379; DOI:10.1158/1535-7163.MCT-07-0487

  
  
• Research Articles: Therapeutics, Targets, and Development

  Calcitrol (1α,25-dihydroxyvitamin D₃) inhibits androgen glucuronidation in prostate cancer cells

  Jenny Kaeding, Julie Bélanger, Patrick Caron, Mélanie Verreault, Alain Bélanger and Olivier Barbier

  Mol Cancer Ther February 1 2008 7 (2) 380-390; DOI:10.1158/1535-7163.MCT-07-0455

  
  
• Research Articles: Therapeutics, Targets, and Development

  IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL⁺ cells

  Elizabeth A. Duncan, Christine A. Goetz, Sarah J. Stein, Katie J. Mayo, Brian J. Skaggs, Karl Ziegelbauer, Charles L. Sawyers and Albert S. Baldwin

  Mol Cancer Ther February 1 2008 7 (2) 391-397; DOI:10.1158/1535-7163.MCT-07-0305

  
  
• Research Articles: Therapeutics, Targets, and Development

  Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells

  Florence Huguet, Nicole Giocanti, Christophe Hennequin, Martine Croisy, Emmanuel Touboul and Vincent Favaudon

  Mol Cancer Ther February 1 2008 7 (2) 398-406; DOI:10.1158/1535-7163.MCT-07-2023

  
  
• Research Articles: Therapeutics, Targets, and Development

  Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

  Shining Wang, Ping Guo, Xiaomin Wang, Qingyu Zhou and James M. Gallo

  Mol Cancer Ther February 1 2008 7 (2) 407-417; DOI:10.1158/1535-7163.MCT-07-2070

  
  
• Research Articles: Therapeutics, Targets, and Development

  Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium

  Paul Beaudry, Monique Nilsson, Matthew Rioth, Daniela Prox, David Poon, Lanwei Xu, Patrick Zweidler-Mckay, Anderson Ryan, Judah Folkman, Sandra Ryeom and John Heymach

  Mol Cancer Ther February 1 2008 7 (2) 418-424; DOI:10.1158/1535-7163.MCT-07-0568

  
  
• Research Articles: Therapeutics, Targets, and Development

  Adrenocortical carcinoma survival rates correlated to genomic copy number variants

  Elizabeth A. Stephan, Tae-Hoon Chung, Clive S. Grant, Seungchan Kim, Daniel D. Von Hoff, Jeffrey M. Trent and Michael J. Demeure

  Mol Cancer Ther February 1 2008 7 (2) 425-431; DOI:10.1158/1535-7163.MCT-07-0267

  
  
• Research Articles: Therapeutics, Targets, and Development

  In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin

  Li Peng, Ruiwu Liu, Mirela Andrei, Wenwu Xiao and Kit S. Lam

  Mol Cancer Ther February 1 2008 7 (2) 432-437; DOI:10.1158/1535-7163.MCT-07-0575